Emergence of Pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center

被引:0
作者
Ghazi, M. [1 ]
Khanbabaee, G. [2 ]
Fallah, F. [3 ]
Kazemi, B. [4 ]
Mahmoudi, S. [5 ]
Navidnia, M. [3 ]
Pourakbari, B. [5 ]
Bakhshi, B. [6 ]
Goudarzi, H. [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Mofid Children Hosp, Dept Pediat Resp Dis, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Pediat Infect Res Ctr, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Cellular & Mol Biol Res Ctr, Tehran, Iran
[5] Univ Tehran Med Sci, Pediat Infect Dis Res Ctr, Tehran, Iran
[6] Tarbiat Modares Univ, Dept Bacteriol, Tehran, Iran
关键词
P; aeruginosa; Cystic fibrosis; genotyping; Iran;
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background and Objectives: This study was carried out with the objective of determining the genomic variability of P. aeruginosa strains isolated from patients suffering from cystic fibrosis or from environmental cultures collected from different locations in the unit they admitted. Materials and Methods: A total of 57 clinical and environmental P. aeruginosa isolates were genotyped by enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR), and antimicrobial susceptibility testing was performed using the Clinical and Laboratory Standards Institute method. Results: One predominant ERIC profile (type A) was identified in 46 strains (81% of all typed isolates) which was responsible for thirty-nine of 44 clinical isolates (89%) and 7 of 13 environmental isolates (54%). All clinical isolates were susceptible to piperacillin-tazobactam, ceftazidime and cefepime followed by ticarcillin, aztreonam, amikacin and tobramycin (96.5%). Conclusions: In our country CF patients are not segregated from other patients, and transmission of bacteria between these patients and other patients might occur in the wards via personal contact or contaminated environment. Future evaluation for policy of patient segregation is necessary and the elimination of contaminated sources and control of environmental spread and recurrent contamination risk is needed.
引用
收藏
页码:124 / 129
页数:6
相关论文
共 50 条
[41]   Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic [J].
Armstrong, DS ;
Nixon, GM ;
Carzino, R ;
Bigham, A ;
Carlin, JB ;
Robins-Browne, RM ;
Grimwood, K .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (07) :983-987
[42]   Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients [J].
Lang, AB ;
Horn, MP ;
Imboden, MA ;
Zuercher, AW .
VACCINE, 2004, 22 :S44-S48
[43]   Study of IgG antibodies to Pseudomonas aeruginosa in early cystic fibrosis infection [J].
Giordano, A ;
Magni, A ;
Filadoro, F ;
Graziani, C ;
Quattrucci, S ;
Cipriani, P .
MICROBIOLOGICA, 1998, 21 (04) :375-378
[44]   Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates [J].
Tramper-Stranders, G. A. ;
van der Ent, C. K. ;
Molin, S. ;
Yang, L. ;
Hansen, S. K. ;
Rau, M. H. ;
Ciofu, O. ;
Johansen, H. K. ;
Wolfs, T. F. W. .
CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (06) :567-574
[45]   Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection [J].
Pukhalsky, AL ;
Kapranov, NI ;
Kalashnikova, EA ;
Shmarina, GV ;
Shabalova, LA ;
Kokarovtseva, SN ;
Pukhalskaya, DA ;
Kashirskaja, NJ ;
Simonova, OI .
MEDIATORS OF INFLAMMATION, 1999, 8 (03) :159-167
[46]   Evaluating the "Leeds criteria'' for Pseudomonas aeruginosa infection in a cystic fibrosis centre [J].
Proesmans, M ;
Balinska-Miskiewicz, W ;
Dupont, L ;
Bossuyt, X ;
Verhaegen, J ;
Hoiby, N ;
de Boeck, K .
EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (05) :937-943
[47]   GENDER DIFFERENCES IN CYSTIC-FIBROSIS - PSEUDOMONAS-AERUGINOSA INFECTION [J].
DEMKO, CA ;
BYARD, PJ ;
DAVIS, PB .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1995, 48 (08) :1041-1049
[48]   Chronic Pseudomonas aeruginosa Infection and Respiratory Muscle Impairment in Cystic Fibrosis [J].
Dassios, Theodore G. ;
Katelari, Anna ;
Doudounakis, Stavros ;
Dimitriou, Gabriel .
RESPIRATORY CARE, 2014, 59 (03) :363-370
[49]   Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches [J].
Lund-Palau, Helena ;
Turnbull, Andrew R. ;
Bush, Andrew ;
Bardin, Emmanuelle ;
Cameron, Loren ;
Soren, Odel ;
Wierre-Gore, Natasha ;
Alton, Eric W. F. W. ;
Bundy, Jacob G. ;
Connett, Gary ;
Faust, Saul N. ;
Filloux, Alain ;
Freemont, Paul ;
Jones, Andy ;
Khoo, Valerie ;
Morales, Sandra ;
Murphy, Ronan ;
Pabary, Rishi ;
Simbo, Ameze ;
Schelenz, Silke ;
Takats, Zoltan ;
Webb, Jeremy ;
Williams, Huw D. ;
Davies, Jane C. .
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (06) :685-697
[50]   Epidemiology of Clonal Pseudomonas aeruginosa Infection in a Canadian Cystic Fibrosis Population [J].
Middleton, Maggie A. ;
Layeghifard, Mehdi ;
Klingel, Michelle ;
Stanojevic, Sanja ;
Yau, Yvonne C. W. ;
Zlosnik, James E. A. ;
Coriati, Adele ;
Ratjen, Felix A. ;
Tullis, Elizabeth D. ;
Stephenson, Anne ;
Wilcox, Pearce ;
Freitag, Andreas ;
Chilvers, Mark ;
McKinney, Martha ;
Lavoie, Annick ;
Wang, Pauline W. ;
Guttman, David S. ;
Waters, Valerie J. .
ANNALS OF THE AMERICAN THORACIC SOCIETY, 2018, 15 (07) :827-836